Cassava Sciences, Inc. (SAVA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Cassava Sciences, Inc. (SAVA)
Company Performance

Current Price

as of Oct 16, 2024

$29.63

P/E Ratio

N/A

Market Cap

$1.42B

Description

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Metrics

Overview

  • HQAustin, TX
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSAVA
  • Price$29.63+4.85%

Trading Information

  • Market Cap$1.42B
  • Float88.34%
  • Average Daily Volume (1m)2,144,804
  • Average Daily Volume (3m)2,839,489
  • EPS-$0.39

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income$6.15M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$66.90M
  • EV$363.30M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B7.52
Documents
SEC Filings
8-K (2024-10-08)
8-K (2024-09-27)
8-K (2024-09-17)
8-K (2024-09-09)
8-K (2024-08-08)
8-K (2024-07-22)
8-K (2024-07-18)
8-K (2024-07-17)
8-K (2024-07-01)
8-K (2024-05-22)
8-K (2024-05-13)
8-K (2024-05-10)
8-K (2024-05-08)
8-K (2024-05-01)
8-K (2024-04-15)
8-K (2024-02-28)
8-K (2024-02-07)
8-K (2024-01-03)
8-K (2023-12-12)
8-K (2023-12-11)
8-K (2023-11-07)
8-K (2023-09-13)
8-K (2023-08-03)
8-K (2023-07-05)
8-K (2023-05-08)
8-K (2023-05-01)
8-K (2023-03-17)
8-K (2023-03-10)
8-K (2023-02-28)
8-K (2023-01-24)
10-Q (2024-08-08)
10-Q (2024-05-10)
10-Q (2023-11-07)
10-Q (2023-08-03)
10-Q (2023-05-01)
10-K (2024-02-28)
10-K (2023-02-28)
Wikipedia
Cassava_Sciences
Factset Street Account
Cassava Sciences trading lower; STAT News article cited ($18.59, -1.30) (2023-10-30T16:48:15Z)
Cassava Sciences trading lower (30%) after hours; issues statement on leaked CUNY report ($17.54, 0.00) (2023-10-13T04:14:40Z)
Cassava Sciences reports Q3 EPS ($0.61) vs year-ago ($0.51) ($21.38, 0.00) (2023-11-07T14:04:43Z)
Cassava Sciences completes patient Enrollment for pivotal Phase 3 trial of oral Simufilam in Alzheimer's Disease ($16.64, 0.00) (2023-10-02T13:02:30Z)
Cassava Sciences completes enrollment for pivotal Phase 3 program of Simufilam in Alzheimer's Disease ($22.70, 0.00) (2023-11-07T14:02:34Z)
Cassava Sciences announces MRI data suggests Simufilam is not associated with Amyloid-related Imaging Abnormalities (ARIA) ($14.77, 0.00) (2023-10-25T13:18:10Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2018Q3
Earnings Report (2018-10-29)
Factset
Factset Business Description